Skip to main content

Patient Representative Committee

The patient voice in clinical trial research

Canadian Cancer Trials Group (CCTG) recognizes the value and importance of engaging patients, including the patient voice in all aspects of the clinical trial life-cycle. Integrating the patient perspective into the CCTG’s overall strategic agenda ensures the research agenda has the greatest impact on cancer patients in Canada and around the world.

CCTG has implemented a model of dedicated public and patient involvement by including the Patient Representative, who are patient volunteers recruited to disease site committees similar to academic committee members with a three year extendable term.

  • The role of the CCTG Patient Representative has evolved to integrate the patient perspective into many steps of the research process with the aim of:
    • research questions that matter to patients, and
    • improved accrual
  • CCTG is committed to implementing best practices and materials to foster and facilitate patient engagement

If you are looking for more information about the CCTG Patient Representative Committee please contact Yvonne Murray, Patient Engagement Lead for information.

CCTG is currently looking for volunteers for these roles:

For more information about current committee openings please contact Nancy Dusharm.

CCTG Patient Representative Committee

Dan Renouf and Gayl

Improving survival for people with pancreatic cancer

Stories of research impact, CCS Research Impact Report. An international clinical trial has changed the way doctors treat pancreatic cancer around the world.

More >>
 
CCTG HD12 a hematology trial investigating targeted therapy for early-stage Hodgkin lymphoma opens in Canada

CCTG HD12 a hematology trial investigating targeted therapy for early-stage Hodgkin lymphoma opens in Canada

Researchers will compare the usual treatment for Hodgkin lymphoma, with a new treatment that takes the standard combination drug treatment replacing one of the drugs with brentuximab vedotin that may be more effective and cause fewer side effects for patients.

More >>
 
IND.227 trial were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Results from a new study show improved survival for patients with pleural mesothelioma

Late-breaking results for the IND.227 trial were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase III international study evaluated the use of the immunotherapy drug pembrolizumab combined with platinum-pemetrexed chemotherapy as a first-line treatment for pleural mesothelioma patients.

More >>
 
CX5 | SHAPE trial demonstrates that reduced radicality of surgical intervention can improve quality of life for patients

New study results show that simple hysterectomy is a safe option for women with early-stage, low-risk cervical cancer

A simple hysterectomy with pelvic node dissection is a safe treatment option for women with low-risk early-stage cervical cancer and may help improve quality of life, according to results from the CX5/SHAPE study, an international phase III clinical trial led by the Canadian Cancer Trials Group.

More >>